Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor

Anti-Cancer Drugs

Volumn 13, Issue 1, 2002, Pages 67-74

  Wenzel, Catharina ^a   Locker, Gottfried J ^a   Schmidinger, Manuela ^a   Rudas, Margarethe ^a   Taucher, Susanne ^a   Gnant, Michael F X ^a   Jakesz, Raimund ^a   Steger, Guenther G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Epidoxorubicin; Neoadjuvant

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MENOPAUSE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PALLIATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 0036177015     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200201000-00008     Document Type: Article

References (30)

1. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: From metastatic to adjuvant setting
2. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
3. Improved disease free survival and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
4. Adjuvant chemotherapy of sequential docetaxel (D) and adriamycin (A) in patients with stage II and III completely resected breast cancer
5. Pilot study of primary, chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer
6. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study
7. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study
8. Front-line treatment of advanced breast cancer with docetaxel and epidoxorubicin: A multicenter phase II study
9. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196
10. Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Institute
11. A prospective randomized phaseIII trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
12. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
13. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
14. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: A multicenter, community-based feasibility trial
15. Paclitaxel and recombinant human granulocyte-colony stimulating factor as initial chemotherapy for metastatic breast cancer
16. Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistent breast cancer
17. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
18. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC
19. Reporting results of cancer treatment
20. Non-parametric estimation for incomplete observations
21. Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
22. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
23. Clinical phase II evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)
24. Doxorubicin and paclitaxel: A highly active combination in the treatment of metastatic breast cancer
25. Phase II of doxorubicin/taxol in metastatic breast cancer
26. 6 Cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): Preliminary results of a randomized phase II trial of GIREC SO1
27. Docetaxel (D) plus high dose epirubicin (E) with lenograstim (L) support as first line therapy in advanced breast cancer (ABC). A phase II study
28. Doxorubicin and Taxotere: A pharmacokinetic study of the combination in advanced breast cancer
29. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
30. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol